trending Market Intelligence /marketintelligence/en/news-insights/trending/XNPuxJgRdSHEnAZoh7YIsA2 content esgSubNav
In This List

Orthocell completes A$1.5M share placement, to launch share purchase plan

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Orthocell completes A$1.5M share placement, to launch share purchase plan

Orthocell Ltd. completed a placement of about 4,411,765 fully paid ordinary shares priced at 34 Australian cents apiece, raising A$1.5 million before costs.

The company also plans to launch a non-underwritten share purchase plan, under which each eligible shareholder can subscribe for up to A$15,000 of new shares, priced at 34 cents apiece.

The share purchase plan is expected to close Dec. 29.

Orthocell will use proceeds to accelerate commercialization of its CelGro collagen medical device in Europe as well as progress U.S. regulatory approvals and key studies. Proceeds will also go toward developing the company's research and development pipeline products.

Shaw and Partners is acting as sole lead manager for both transactions.